Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study.

@article{Pollow2004SafetyAT,
  title={Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study.},
  author={K. Pollow and W. Schoenegg and H. Koelbl and R. Kreienberg and A. Dubois and D. Elling and K. Winzer and U. K{\"o}hler and G. Hoffmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={594}
}
  • K. Pollow, W. Schoenegg, +6 authors G. Hoffmann
  • Published 2004
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 594 Background: Goserelin (G) reduces ovarian production of luteinizing hormone and estrogen to postmenopausal values, but does not inhibit estrogens in peripheral tissues. Adding an agent that reduces peripheral estrogen production, such as the steroidal aromatase inactivator exemestane (E), may optimally decrease estrogen levels. The climacteric symptoms expected with a G/E regimen may be relieved with tibolone (T). The randomized, multicenter ADAGIO trial is testing the safety and… CONTINUE READING
    4 Citations
    A review of exemestane in the management of breast cancer
    • 2
    Neoadjuvant endocrine therapy for breast cancer: past, present and future
    • 16
    Agonistes de la GnRH en pathologie mammaire